United Therapeutics Corporation
UTHR
$556.82
-$5.27-0.94%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.17B | 3.18B | 3.13B | 3.08B | 2.99B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.17B | 3.18B | 3.13B | 3.08B | 2.99B |
| Cost of Revenue | 425.30M | 384.40M | 356.90M | 339.10M | 329.30M |
| Gross Profit | 2.74B | 2.80B | 2.77B | 2.74B | 2.66B |
| SG&A Expenses | 746.60M | 732.60M | 701.80M | 674.10M | 660.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.71B | 1.67B | 1.60B | 1.53B | 1.52B |
| Operating Income | 1.46B | 1.52B | 1.53B | 1.54B | 1.48B |
| Income Before Tax | 1.61B | 1.71B | 1.67B | 1.62B | 1.56B |
| Income Tax Expenses | 321.30M | 379.20M | 394.70M | 374.90M | 353.20M |
| Earnings from Continuing Operations | 1.29K | 1.33K | 1.27K | 1.24K | 1.21K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.29B | 1.33B | 1.27B | 1.24B | 1.21B |
| EBIT | 1.46B | 1.52B | 1.53B | 1.54B | 1.48B |
| EBITDA | 1.55B | 1.60B | 1.61B | 1.62B | 1.56B |
| EPS Basic | 29.33 | 30.18 | 28.51 | 27.71 | 27.11 |
| Normalized Basic EPS | 23.40 | 23.91 | 23.79 | 23.93 | 22.91 |
| EPS Diluted | 27.09 | 27.90 | 26.38 | 25.61 | 25.05 |
| Normalized Diluted EPS | 21.63 | 22.12 | 22.02 | 22.12 | 21.17 |
| Average Basic Shares Outstanding | 175.70M | 177.10M | 178.50M | 179.30M | 178.60M |
| Average Diluted Shares Outstanding | 190.10M | 191.50M | 192.90M | 194.00M | 193.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |